<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757757</url>
  </required_header>
  <id_info>
    <org_study_id>CMCS110A2101</org_study_id>
    <nct_id>NCT00757757</nct_id>
  </id_info>
  <brief_title>A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases</brief_title>
  <official_title>A Phase I/II Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MCS110 in Patients With Prostate Cancer and Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of MCS110 in patients with prostate cancer
      and bone metastases
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and characteristics of treatment related dose-limiting-toxicities in dose escalation phase</measure>
    <time_frame>every cycle - (cycle = 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Type and frequency of adverse drug reactions and serious adverse drug reactions</measure>
    <time_frame>every cycle - (cycle = 28 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in markers of bone resorption and formation (pre- vs. post-treatment)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>MCS110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCS110</intervention_name>
    <description>Anti-M-CSF antibody</description>
    <arm_group_label>MCS110</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with asymptomatic castrate-resistant prostate cancer with bone metastases who
             have not received any bisphosphonates in the 12 months prior to enrollment

          -  18 years old and over

        Exclusion Criteria:

          -  Plan to be on cytotoxic or biologic therapy during study

          -  Active dental problems

          -  Active heart complications

          -  Active infection

          -  Patients with moderate to severe swelling due to fluid

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NV Cancer Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTRC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <disposition_first_submitted>February 9, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 9, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 12, 2013</disposition_first_posted>
  <last_update_submitted>February 9, 2013</last_update_submitted>
  <last_update_submitted_qc>February 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>bone metastases</keyword>
  <keyword>anti-M-CSF</keyword>
  <keyword>M-CSF antibody</keyword>
  <keyword>M-CSF</keyword>
  <keyword>Prostate Cancer with bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

